Drug Profile
Dulanermin
Alternative Names: AMG-951; PRO 1762; Recombinant human Apo2L/TRAIL; RG 3639; Rh-Apo2L - Amgen/Genentech; rhApo2L/TRAIL; TNF-related apoptosis-inducing ligand; TRAIL/Apo2LLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Amgen
- Developer Amgen; Genentech
- Class Antineoplastics; Recombinant proteins
- Mechanism of Action Apoptosis stimulants; TRAIL receptor 1 agonists; TRAIL receptor 2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Colorectal cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer
Most Recent Events
- 26 Jul 2011 Discontinued - Phase-I for Colorectal cancer in USA (IV)
- 15 Jun 2011 Genentech and Amgen terminate a phase I/II trial in Non-Hodgkin's lymphoma in Australia, European Union, New Zealand and USA(NCT00400764)
- 21 Apr 2011 Discontinued - Phase-I/II for Non-Hodgkin's lymphoma in Australia (IV)